Berlirem is a pharmaceutical company developing new concepts for continuous parenteral application of Levodopa and related compounds for therapy of Parkinson’s Disease.
Levodopa is highly effective in treating the symptoms of Parkinson’s Disease and has been the gold standard of Parkinson’s Disease therapy for more than 50 years. Yet, conventional oral Levodopa therapy does not exploit the full therapeutic potential of this drug. There remains an unmet need for more stable and continuous drug delivery.
To solve this important challenge of Parkinson’s Disease therapy Berlirem is developing prodrugs of levodopa and related compounds suitable for continuous subcutaneous infusion therapy.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT Privacy & Cookies Policy
